IRLAB Therapeutics AB publ announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced total revenue - ar was SEK 0 compared to SEK 106,000 a year ago. Operating loss was SEK 26.521 million compared to SEK 26.103 million a year ago. Net loss was SEK 26.629 million compared to SEK 26.154 million a year ago. For the half year, total revenue - ar was SEK 0 compared to SEK 329,000 a year ago. Operating loss was SEK 46.487 million compared to SEK 45.164 million a year ago. Net loss was SEK 46.670 million compared to SEK 45.272 million a year ago.